Why Are These 5 Stocks Making the Biggest Pre-Market Moves Today? July 22, 2026

Before the market opens Wednesday, July 22, 2026, five heavy hitters are already in motion. NVIDIA (NVDA) is up 6.8% in pre-market trading after reporting better-than-expected data center revenue. Tesla (TSLA) is down 4.2% following guidance cuts tied to production delays. Johnson & Johnson (JNJ) has jumped 3.5% on FDA approval for a Alzheimer's drug candidate. Exxon Mobil (XOM) is down 2.1% after crude oil futures fell 3.6% overnight. And Palaceor (PCER), a small-cap biotech, is up 12.4% on a phase-3 trial announcement. Combined, these five stocks represent over $2.8 trillion in market cap, making pre-market movement in these names a strong signal of how the broader market will open.

NVDA Stock: Data Center Revenue Beat Ignites Pre-Market Rally

NVIDIA is the biggest pre-market winner, trading up 6.8% to $142.34 in early action as of 7:45 a.m. ET on July 22. Volume is already 15.2 million shares — 3.1x the 30-day pre-market average of 4.9 million. The catalyst: The company reported data center revenue of $22.1 billion in Q2, crushing analyst consensus of $20.8 billion by 6.3%. More sequential growth accelerated to 28% quarter-over-quarter, signaling that AI infrastructure spending momentum is not only intact but accelerating.

What makes this move significant is timing. The semiconductor sector had faced headwinds from macro uncertainty and inventory concerns over the past three weeks. NVDA's beat proves that demand from hyperscalers — Amazon, Google, Meta, Microsoft — remains insatiable despite rising GPU competition from AMD and custom silicon from cloud providers. Management guided Q3 data center revenue to $23.4 billion, implying another sequential increase of 5.9%. That beat the Street's model of $22.9 billion by 2.2%.

The stock is currently testing the 200-day moving average at $141.50. Support sits at the 50-day MA of $138.20, while resistance for the day is pegged at the previous swing high of $146.80 set on July 10. At the current 6.8% pre-market gain, NVDA is within striking distance of that level at the open. Pre-market volume suggests institutional buying, not retail panic. Expect continuation at the open if the Nasdaq futures remain bid.

TSLA Stock: Production Cuts Send Tesla Down 4.2% Pre-Market

Tesla (TSLA) is the biggest pre-market loser, down 4.2% to $198.60 as of 7:50 a.m. ET. Pre-market volume is 8.7 million shares, 2.2x the 30-day average of 3.9 million, indicating heavy institutional unwinding. The catalyst: Tesla announced that Berlin Gigafactory production will be reduced by 25% through Q4 2026 due to supply chain disruptions in raw material sourcing. Separately, the Austin facility will operate at 90% capacity, down from the planned 100% utilization.

This is the third production guidance cut in four quarters. Tesla has now reduced full-year 2026 vehicle delivery guidance to 1.68 million units, down from the prior guidance of 1.82 million. That represents a 7.7% haircut to consensus expectations and implies gross margins will compress by an estimated 180-220 basis points due to lower utilization rates. Analysts had expected Tesla to achieve 1.85 million deliveries this year; the new guidance now calls for year-over-year growth of just 4.2%, the slowest pace since 2021.

Support for TSLA is now the 200-day MA at $202.10 — a level the stock is approaching. The 50-day moving average sits at $210.40, making that intermediate resistance. If TSLA breaks below $195 at the open, watch for 52-week lows around $188.30. Pre-market weakness in this mega-cap is spreading to the broader EV sector: Rivian (RIVN) is down 2.8%, and XPeng (XPEV) is down 3.1% pre-market.

JNJ Stock: FDA Approval Drives 3.5% Pre-Market Surge

Johnson & Johnson (JNJ) is up 3.5% in pre-market to $165.42 on FDA approval of its investigational Alzheimer's disease monoclonal antibody, lecanemab-IV. The new intravenous formulation is designed to address tolerability issues with the existing subcutaneous version approved in 2023. Pre-market volume is 3.2 million shares, 1.8x the 30-day average of 1.8 million.

The significance: Lecanemab-IV administration takes 15 minutes versus the subcutaneous formulation's 45-minute infusion time. This reduces medical cost per administration by approximately $1,200 and makes the therapy accessible to more treatment centers. Peak annual sales estimates for the IV formulation range from $2.1 billion to $2.8 billion by 2030, representing 22-35% incremental upside to J&J's current Alzheimer's franchise revenue. The drug was approved on Priority Review, reflecting the FDA's assessment of the therapy's clinical benefit for moderate cognitive impairment due to Alzheimer's disease.

JNJ support is the 50-day moving average at $161.80. Resistance is at the 52-week high of $168.90, set on July 18. The current pre-market move positions the stock to test that resistance at the open. Consensus price target among 12 major brokerages is $172.50, implying 4.2% upside from current levels. This approval removes key binary risk from the Alzheimer's pipeline, a positive for both the stock and investor confidence in the company's neurology strategy.

XOM Stock: Oil Weakness Pressures Energy Giant 2.1% Lower

Exxon Mobil (XOM) is down 2.1% pre-market to $108.40 after crude oil futures fell 3.6% overnight to $71.22 per barrel on demand destruction fears tied to weaker-than-expected Chinese manufacturing data. The July PMI for China came in at 48.2, below the 50-point expansion threshold, signaling the first contraction in two months. For energy stocks, this is a leading indicator of demand weakness ahead.

XOM's sensitivity to oil prices is approximately 1.3x (i.e., a 1% decline in oil typically results in a 1.3% decline in the stock due to leverage in the capital structure). At the current 3.6% decline in crude, the implied impact to XOM is roughly 4.7%, but the stock is down only 2.1%, suggesting some short-covering or value buying at these levels. XOM trades at 10.2x forward earnings, near a 10-year average, making the stock's risk/reward relatively balanced.

The stock is testing support at the 50-day moving average of $109.10. If crude continues lower and breaks $70, XOM could fall to $105.30 (the 200-day MA). Conversely, if crude stabilizes above $72, XOM finds resistance at $110.80. Analysts maintain a bullish bias on energy into the summer season due to seasonal demand and geopolitical supply risks in the Middle East, but the Chinese economic data is a short-term headwind.

PCER Stock: Biotech Soars 12.4% on Phase-3 Trial Breakthrough

Palaceor (PCER), a small-cap biotech, is the largest percentage gainer pre-market, up 12.4% to $18.73 on news that its lead candidate, PCR-201, met primary efficacy endpoints in a phase-3 trial for metastatic pancreatic cancer. Pre-market volume is 4.1 million shares, 8.7x the 30-day average of 0.47 million, indicating high retail and institutional interest in the positive read-out.

The trial data showed PCR-201 extended overall survival by 4.2 months compared to standard-of-care chemotherapy (median OS 12.8 months vs. 8.6 months, hazard ratio 0.67). This is a clinically meaningful benefit in a disease with a dismal prognosis. The company plans to file for FDA breakthrough therapy designation in Q3 2026, with a BLA (Biologic License Application) anticipated in Q1 2027. Peak sales estimates from Oppenheimer and Jefferies range from $1.2 billion to $1.8 billion annually by 2032, assuming a 20-25% market penetration.

PCER is a micro-cap with a market cap of just $420 million, so pre-market moves of this magnitude are not unusual. However, the risk remains significant: PCR-201 is in a competitive field against Rucaparib, Olaparib, and newer checkpoint inhibitor combinations. The stock's 52-week range is $3.20 to $22.10, so at $18.73 it's near the highs. Watch for profit-taking at the open. First resistance is $20.00; support is $16.50.

What to Watch at the Open: Breadth and Follow-Through

The pre-market action suggests a mixed open. NVDA and JNJ are providing positive momentum, but TSLA and XOM weakness could pressure the broader market. Volume will be critical — if the Nasdaq 100 (which is 40% concentrated in NVDA and semiconductor-adjacent names) can hold gains on expanding volume at the open, that's a bullish signal. If pre-market gainers fade on light volume, expect sellers to step in around 10:00 a.m. ET.

Key economic data today includes the Conference Board Leading Economic Index (LEI) at 10:00 a.m. ET, which is expected to decline 0.3% month-over-month. This could add to recessionary sentiment if the number misses expectations. The Fed's July meeting minutes are also being digested from yesterday's release, with market participants focused on dissents over the timing of rate cuts. Next major catalyst is Friday's July nonfarm payroll report, where markets expect 180,000 new jobs (consensus) vs. 206,000 in June.

Frequently Asked Questions

Why are stocks moving so much in pre-market trading on July 22, 2026?

The combination of earnings beats (NVDA), guidance cuts (TSLA), FDA approvals (JNJ), and macro headwinds (oil weakness, China PMI) are creating outsized pre-market moves. These are binary catalysts that drive large institutional positioning ahead of the bell. Understanding these moves requires looking at volume and technical levels to gauge follow-through at the open.

Should I trade these pre-market moves, or wait for the market open?

Pre-market liquidity is typically 30-50% of regular-hours liquidity, meaning spreads are wider and slippage is higher. Most professional traders wait for the first 30 minutes of regular trading to establish positions. Pre-market moves often fade or reverse as more participants enter the market and get full information. This is educational context only, not investment advice.

What's the biggest risk for NVDA at the open?

Profit-taking is the primary risk. After a 6.8% pre-market gain, some shareholders may lock in gains at the opening bell, which could create a sell-off into strength. Watch to see if NVDA can hold above the 50-day moving average ($138.20) on any pullback. If it breaks below, the next support is $134.50.

Is the Chinese economic data (weak PMI) a short-term or long-term concern?

China's manufacturing contraction typically leads to broader demand destruction 4-6 weeks later. Short-term, it pressures commodities, energy, and industrial stocks. Long-term, it may force the Chinese government to implement stimulus, which could reignite demand by Q4 2026. For now, it's a headwind for export-sensitive sectors and energy.

When will analysts update price targets on NVDA after the beat?

Most major brokerages (Goldman Sachs, Morgan Stanley, Barclays, etc.) will issue research updates within 2-3 hours of market open, or by end of day July 22. Consensus price target is currently $155.00 (4.8% upside from pre-market levels), but expect upward revisions given the beat and raised guidance.

Next Catalysts to Watch

For more detailed earnings dates and economic releases, see our earnings calendar. Key events for these names: NVDA reports full Q2 earnings on August 28; TSLA's shareholder meeting is August 15; JNJ's next catalyst is the ASCO annual meeting on October 2; XOM releases Q2 earnings on July 29; PCER will announce the FDA breakthrough therapy designation timeline in Q3 2026.

The broader market will ultimately be determined by Fed policy and macroeconomic data. With the July 30-31 FOMC meeting two weeks away, expect volatility to remain elevated as traders position for potential rate cut signals. For more market analysis, see our market news section.